FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087355102> ?p ?o ?g. }

• W3087355102 endingPage "5108" @default.
• W3087355102 startingPage "5098" @default.
• W3087355102 abstract "Abstract Although lower grade gliomas are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene and are less aggressive than primary glioblastoma, they nonetheless generally recur. IDH1-mutant patients are increasingly being treated with temozolomide, but early detection of response remains a challenge and there is a need for complementary imaging methods to assess response to therapy prior to tumor shrinkage. The goal of this study was to determine the value of magnetic resonance spectroscopy (MRS)–based metabolic changes for detection of response to temozolomide in both genetically engineered and patient-derived mutant IDH1 models. Using 1H MRS in combination with chemometrics identified several metabolic alterations in temozolomide-treated cells, including a significant increase in steady-state glutamate levels. This was confirmed in vivo, where the observed 1H MRS increase in glutamate/glutamine occurred prior to tumor shrinkage. Cells labeled with [1–13C]glucose and [3–13C]glutamine, the principal sources of cellular glutamate, showed that flux to glutamate both from glucose via the tricarboxylic acid cycle and from glutamine were increased following temozolomide treatment. In line with these results, hyperpolarized [5–13C]glutamate produced from [2–13C]pyruvate and hyperpolarized [1–13C]glutamate produced from [1–13C]α-ketoglutarate were significantly higher in temozolomide-treated cells compared with controls. Collectively, our findings identify 1H MRS-detectable elevation of glutamate and hyperpolarized 13C MRS-detectable glutamate production from either pyruvate or α-ketoglutarate as potential translatable metabolic biomarkers of response to temozolomide treatment in mutant IDH1 glioma. Significance: These findings show that glutamate can be used as a noninvasive, imageable metabolic marker for early assessment of tumor response to temozolomide, with the potential to improve treatment strategies for mutant IDH1 patients." @default.
• W3087355102 created "2020-09-25" @default.
• W3087355102 creator A5009633669 @default.
• W3087355102 creator A5015797009 @default.
• W3087355102 creator A5023293212 @default.
• W3087355102 creator A5035221576 @default.
• W3087355102 creator A5051136743 @default.
• W3087355102 creator A5057989350 @default.
• W3087355102 creator A5060105335 @default.
• W3087355102 creator A5066154146 @default.
• W3087355102 creator A5073732331 @default.
• W3087355102 creator A5088197113 @default.
• W3087355102 creator A5088730125 @default.
• W3087355102 creator A5088735047 @default.
• W3087355102 date "2020-11-13" @default.
• W3087355102 modified "2023-10-17" @default.
• W3087355102 title "Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment" @default.
• W3087355102 cites W1144254266 @default.
• W3087355102 cites W1812256879 @default.
• W3087355102 cites W1968391269 @default.
• W3087355102 cites W1970855001 @default.
• W3087355102 cites W2006128031 @default.
• W3087355102 cites W2019822930 @default.
• W3087355102 cites W2027244170 @default.
• W3087355102 cites W2038979894 @default.
• W3087355102 cites W2042524329 @default.
• W3087355102 cites W2050805040 @default.
• W3087355102 cites W2058417905 @default.
• W3087355102 cites W2060484108 @default.
• W3087355102 cites W2060959699 @default.
• W3087355102 cites W2087481249 @default.
• W3087355102 cites W2099320954 @default.
• W3087355102 cites W2101246344 @default.
• W3087355102 cites W2117036448 @default.
• W3087355102 cites W2117950076 @default.
• W3087355102 cites W2128083719 @default.
• W3087355102 cites W2140821112 @default.
• W3087355102 cites W2147387301 @default.
• W3087355102 cites W2148967592 @default.
• W3087355102 cites W2162160603 @default.
• W3087355102 cites W2164675211 @default.
• W3087355102 cites W2270106090 @default.
• W3087355102 cites W2286067421 @default.
• W3087355102 cites W2301401527 @default.
• W3087355102 cites W2461966769 @default.
• W3087355102 cites W2496785181 @default.
• W3087355102 cites W2562161487 @default.
• W3087355102 cites W2567621550 @default.
• W3087355102 cites W2588760673 @default.
• W3087355102 cites W2625742115 @default.
• W3087355102 cites W2755660258 @default.
• W3087355102 cites W2805756200 @default.
• W3087355102 cites W2890068857 @default.
• W3087355102 cites W2891704147 @default.
• W3087355102 cites W2900064183 @default.
• W3087355102 cites W2901018275 @default.
• W3087355102 cites W2903061646 @default.
• W3087355102 cites W2904022363 @default.
• W3087355102 cites W2945329147 @default.
• W3087355102 cites W2963110900 @default.
• W3087355102 cites W2965863523 @default.
• W3087355102 cites W2979914870 @default.
• W3087355102 cites W3045093497 @default.
• W3087355102 cites W3047515231 @default.
• W3087355102 cites W4211022706 @default.
• W3087355102 cites W4211132876 @default.
• W3087355102 doi "https://doi.org/10.1158/0008-5472.can-20-1314" @default.
• W3087355102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7669718" @default.
• W3087355102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32958546" @default.
• W3087355102 hasPublicationYear "2020" @default.
• W3087355102 type Work @default.
• W3087355102 sameAs 3087355102 @default.
• W3087355102 citedByCount "16" @default.
• W3087355102 countsByYear W30873551022021 @default.
• W3087355102 countsByYear W30873551022022 @default.
• W3087355102 countsByYear W30873551022023 @default.
• W3087355102 crossrefType "journal-article" @default.
• W3087355102 hasAuthorship W3087355102A5009633669 @default.
• W3087355102 hasAuthorship W3087355102A5015797009 @default.
• W3087355102 hasAuthorship W3087355102A5023293212 @default.
• W3087355102 hasAuthorship W3087355102A5035221576 @default.
• W3087355102 hasAuthorship W3087355102A5051136743 @default.
• W3087355102 hasAuthorship W3087355102A5057989350 @default.
• W3087355102 hasAuthorship W3087355102A5060105335 @default.
• W3087355102 hasAuthorship W3087355102A5066154146 @default.
• W3087355102 hasAuthorship W3087355102A5073732331 @default.
• W3087355102 hasAuthorship W3087355102A5088197113 @default.
• W3087355102 hasAuthorship W3087355102A5088730125 @default.
• W3087355102 hasAuthorship W3087355102A5088735047 @default.
• W3087355102 hasBestOaLocation W30873551021 @default.
• W3087355102 hasConcept C104317684 @default.
• W3087355102 hasConcept C127848430 @default.
• W3087355102 hasConcept C143065580 @default.
• W3087355102 hasConcept C170493617 @default.
• W3087355102 hasConcept C181199279 @default.
• W3087355102 hasConcept C185592680 @default.
• W3087355102 hasConcept C2777150147 @default.
• W3087355102 hasConcept C2777389519 @default.

• next